Laurus Labs Posts ₹16.53 Billion Revenue In September Quarter, Net Profit At ₹1.95 Billion

Key Developments  
- Consolidated revenue from operations stood at ₹16.53 billion for Q2 FY26  
- Net profit for the quarter reached ₹1.95 billion, indicating resilient margins despite sectoral headwinds  
- The company’s API and Finished Dosage Form (FDF) segments contributed significantly to topline growth  
- Laurus Biologics continued to expand its footprint in biologics manufacturing and R&D  
- Management reaffirmed its focus on innovation, capacity expansion, and regulatory compliance across global markets  
- The company maintained strong operational discipline and cost controls, supporting profitability  

These results underscore Laurus Labs’ strategic execution and diversified portfolio strength, positioning it well for sustained growth in regulated markets.

Sources: Laurus Labs Financial Results Portal [4], Mint [5], The Hindu BusinessLine